Related Experiment Videos
Newer drugs in leprosy.
1Laboratoire de Bacteriologie, Faculte de Medecine Pitie-Salpetriere 75634 Paris 13, France.
Summary
New antibiotics like fluoroquinolones and macrolides show superior leprosy treatment activity compared to standard drugs. A combination therapy (ROM) is recommended for single-lesion leprosy.
Area of Science:
- Pharmacology
- Infectious Diseases
- Microbiology
Background:
- Leprosy treatment historically relied on dapsone and clofazimine.
- Recent advancements have identified new drug classes effective against Mycobacterium leprae.
Purpose of the Study:
- To evaluate the efficacy of novel antibiotics against Mycobacterium leprae.
- To compare the antileprosy activity of new drugs with standard treatments.
Main Methods:
- Studies in mouse models and human clinical trials.
- Assessment of drug combinations including fluoroquinolones, cyclines, and macrolides.
- Clinical trials compared novel drug regimens to dapsone and clofazimine.
Main Results:
- Ofloxacin, minocycline, and clarithromycin demonstrated superior antileprosy activity individually and in combination.
- A single dose of ofloxacin (400 mg) + minocycline (100 mg) killed 68-98% of M. leprae.
- A single dose of ROM (rifampin 600 mg + ofloxacin 400 mg + minocycline 100 mg) killed >99% of M. leprae.
- WHO recommended single-dose ROM for paucibacillary leprosy in 1997.
Conclusions:
- Novel antibiotics, particularly fluoroquinolones and macrolides, offer significantly improved treatment options for leprosy.
- Single-dose ROM therapy is highly effective for single-lesion paucibacillary leprosy.
- Emerging drugs like moxifloxacin and rifapentine show promise for future leprosy treatment.